Mobilizing antitumour immunity through vaccination potentially constitutes a powerful
anticancer strategy but has not yet provided robust clinical benefits in large patient …

Immunotherapy using dendritic cell (DC)-based vaccination is an approved approach for
harnessing the potential of a patient's own immune system to eliminate tumor cells in …

The strategy of combining a vaccine with immune checkpoint inhibitors has been widely
investigated in cancer management, but the complete response rate for this strategy is still …

Dendritic cells (DC) are specialized immune cells that play a critical role in promoting an
immune response against Ags, which can include foreign pathogenic Ags and self-tumor …

Purpose Vitiligo-like depigmentation in patients with melanoma may be associated with
more favorable clinical outcome. We conducted a systematic review of patients with stage III …

After stimulation, dendritic cells (DCs) mature and migrate to draining lymph nodes to induce
immune responses. As such, autologous DCs generated ex vivo have been pulsed with …

Cancer immunotherapy attempts to harness the power and specificity of the immune system
to treat tumours. The molecular identification of human cancer-specific antigens has allowed …

Therapeutic vaccines represent a viable option for active immunotherapy of cancers that aim
to treat late stage disease by using a patient's own immune system. The promising results …

With the advent of combined immunotherapies, personalized dendritic cell (DC)-based
vaccination could integrate the current standard of care for the treatment of a large variety of …

Dendritic cells (DCs) orchestrate a repertoire of immune responses that bring about
resistance to infection and silencing or tolerance to self. In the settings of infection and …